Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European prospective investigation into cancer and nutrition study
- Kreimer, Aimée R
- Brennan, Paul
- Lang Kuhs, Krystle A
- Waterboer, Tim
- Clifford, Gary
- Franceschi, Silvia
- Michel, Angelika
- Willhauck Fleckenstein, Martina
- Riboli, Elio
- Castellsagué, Xavier
- Hildesheim, Allan
- Fortner, Renée Turzanski
- Kaaks, Rudolf
- Palli, Domenico
- Ljuslinder, Ingrid
- Clavel Chapelon, Françoise
- Boutron Ruault, Marie Christine
- Mesrine, Sylvie
- Trichopoulou, Antonia
- Lagiou, Pagona
- Trichopoulos, Dimitrios
- Peeters, Petra H
- Cross, Amanda J
- Bueno de Mesquita, H. Bas
- Vineis, Paolo
- Larrañaga, Nerea
- Pala, Valeria
- Sánchez, María José
- Navarro, Carmen
- Barricarte, Aurelio
- Tumino, Rosario
- Khaw, Kay Tee
- Wareham, Nicholas
- Boeing, Heiner
- Steffen, Annika
- Travis, Ruth C
- Quirós, J. Ramón
- Weiderpass, Elisabete
- Pawlita, Michael
- Johansson, Mattias
- PANICO, SALVATORE
DOIAbstract
Human papillomavirus (HPV) type 16 (HPV16) causes cancer at several anatomic sites. In the European Prospective Investigation Into Cancer and Nutrition study, HPV16 E6 seropositivity was present more than 10 years before oropharyngeal cancer diagnosis and was nearly absent in controls. The current study sought to evaluate the extent to which HPV16 E6 antibodies are present before diagnosis of anogenital cancers within the same cohort
Add to ORKG